12/18
09:22 am
lgvn
Longeveron to Present at Biotech Showcase 2025 [Yahoo! Finance]
Medium
Report
Longeveron to Present at Biotech Showcase 2025 [Yahoo! Finance]
12/18
09:10 am
lgvn
Longeveron to Present at Biotech Showcase 2025
Medium
Report
Longeveron to Present at Biotech Showcase 2025
12/7
07:33 am
lgvn
Longeveron Inc. (NASDAQ: LGVN) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Low
Report
Longeveron Inc. (NASDAQ: LGVN) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
12/6
08:06 am
lgvn
Longeveron Inc. (NASDAQ: LGVN) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $10.00 price target on the stock.
Medium
Report
Longeveron Inc. (NASDAQ: LGVN) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $10.00 price target on the stock.
12/2
09:05 am
lgvn
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
Low
Report
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024
11/25
08:50 am
lgvn
Longeveron Inc. (NASDAQ: LGVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Longeveron Inc. (NASDAQ: LGVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
11/15
06:59 am
lgvn
We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate [Yahoo! Finance]
Medium
Report
We're Keeping An Eye On Longeveron's (NASDAQ:LGVN) Cash Burn Rate [Yahoo! Finance]
11/12
04:05 pm
lgvn
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update
11/11
09:05 am
lgvn
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
Low
Report
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)
11/4
04:05 pm
lgvn
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
Medium
Report
Longeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
11/4
08:19 am
lgvn
Longeveron Inc. (NASDAQ: LGVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Medium
Report
Longeveron Inc. (NASDAQ: LGVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
10/29
10:00 am
lgvn
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
Medium
Report
Longeveron® Presents Lomecel-B™ Data for Alzheimer’s Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
10/27
03:16 pm
lgvn
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting [Yahoo! Finance]
Low
Report
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting [Yahoo! Finance]
10/27
03:10 pm
lgvn
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
Low
Report
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
10/14
09:05 am
lgvn
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
Medium
Report
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
10/9
09:10 am
lgvn
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting [Yahoo! Finance]
Low
Report
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting [Yahoo! Finance]
10/9
09:05 am
lgvn
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
Low
Report
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
10/7
09:10 am
lgvn
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day [Yahoo! Finance]
Low
Report
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day [Yahoo! Finance]
10/7
09:05 am
lgvn
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
Medium
Report
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
10/2
09:05 am
lgvn
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Medium
Report
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference